Home » Topics » BioWorld Science

BioWorld Science
RSS

Merck & Co. presents new adenosine A2A and/or A2B receptor antagonists

Feb. 18, 2022

New coagulation factor XIa inhibitors synthesized at Janssen Pharmaceutica

Feb. 18, 2022

Monoclonal antibodies in AR-701 cocktail neutralize SARS-CoV-2 Omicron variant

Feb. 18, 2022

Neumora licenses rights to novel M4 receptor PAMs from Vanderbilt for schizophrenia

Feb. 18, 2022

CECR2 promotes breast cancer metastasis through NF-kappaB signaling and immunosuppression

Feb. 18, 2022

Extracellular domains are not effective targets to disrupt intracellular HER2-HER3 tumor signaling

Feb. 18, 2022

CROI 2022: Predicting the future to get ahead of viruses

Feb. 17, 2022

BetterLife reports findings from preclinical neural plasticity study of BETR-001

Feb. 17, 2022

Intellia and ONK enter licensing and collaboration agreement for allogeneic NK cell therapies

Feb. 17, 2022

Insilico Medicine nominates preclinical compound in QPCTL program

Feb. 17, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...